|

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

RECRUITINGPhase 3Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2025-12-01
Est. completion2031-08
Eligibility
Age50 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07241390

Summary

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

* Have established ASCVD and/or CKD

Exclusion Criteria:

* Have type 1 diabetes
* Have had a major heart condition within 60 days prior to screening
* Have New York Heart Association Functional Classification Class IV heart failure

Conditions3

Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.